General Information of Drug (ID: DMWDE9A)

Drug Name
PMID15300839C17 Drug Info
Synonyms GTPL715; BDBM50193413
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44415153
TTD Drug ID
DMWDE9A

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [2]
Etelcalcetide DMHP9BL Secondary hyperparathyroidism 5A51.1 Approved [3]
Encaleret DMQSPFS Autosomal dominant hypocalcemia 5A50.0Y Phase 3 [4]
ASP7991 DM3TN1A Hyperparathyroidism 5A51 Phase 2 [5]
MK-5442 DMHTIGU Osteoporosis FB83.0 Phase 2 [6]
ATF-936 DMWGKHZ Osteoporosis FB83.0 Phase 1 [7]
AXT-914 DM7ZU3B Osteoporosis FB83.0 Phase 1 [8]
R-568 DM5NWPD N. A. N. A. Discontinued in Phase 2 [9]
Ronacaleret DM10ZJP Osteoporosis FB83.0 Discontinued in Phase 2 [10]
NPS-2143 DMQPXLF Osteoporosis FB83.0 Discontinued in Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Extracellular calcium-sensing receptor (CASR) TTBUYHA CASR_HUMAN Antagonist [1]

References

1 N(1)-Arylsulfonyl-N(2)-(1-(1-naphthyl)ethyl)-1,2-diaminocyclohexanes: a new class of calcilytic agents acting at the calcium-sensing receptor. Chembiochem. 2004 Aug 6;5(8):1131-6.
2 Clinical pipeline report, company report or official report of Amgen (2009).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035616)
6 Antagonist for calcium-sensing receptor. JTT-305/MK-5442. Clin Calcium. 2011 Jan;21(1):89-93.
7 ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41.
8 AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone. 2014 Jul;64:204-10.
9 Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther. 1999 Jan;65(1):40-9.
10 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
11 Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Abeta42 prompted by exogenous fibrillary or soluble Abeta25-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease. Biochim Biophys Acta. 2013 Oct;1832(10):1634-52.